Imunon, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IMNN, updated each market day.
IMNN AI Sentiment
AI predicts Imunon, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Imunon, Inc. Common Stock
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Sector
Exchange
Market Cap
$7,743,736
Cap Tier
Employees
20
Headquarters
LAWRENCEVILLE, NJ
Listed Since
July 24, 1995
Website
IMNN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IMNN Volatility
Imunon, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
